These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 17762875)

  • 1. Hunting for ion channel modulators with herpes simplex virus.
    Cortright DN; Buck ME; Krause JE
    Nat Methods; 2007 Sep; 4(9):692-3. PubMed ID: 17762875
    [No Abstract]   [Full Text] [Related]  

  • 2. An HSV vector system for selection of ligand-gated ion channel modulators.
    Srinivasan R; Huang S; Chaudhry S; Sculptoreanu A; Krisky D; Cascio M; Friedman PA; de Groat WC; Wolfe D; Glorioso JC
    Nat Methods; 2007 Sep; 4(9):733-9. PubMed ID: 17676048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present and future of herpes simplex virus type 1 (HSV-1)-based amplicon vectors.
    Epstein AL
    Pathol Biol (Paris); 2005 Feb; 53(1):1-3. PubMed ID: 15620601
    [No Abstract]   [Full Text] [Related]  

  • 4. Construction and production of recombinant herpes simplex virus vectors.
    Goins WF; Krisky DM; Wechuck JB; Huang S; Glorioso JC
    Methods Mol Biol; 2008; 433():97-113. PubMed ID: 18679619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
    Grant KG; Krisky DM; Ataai MM; Glorioso JC
    Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of lytic cycle replication of Kaposi's sarcoma-associated herpesvirus by herpes simplex virus type 1: involvement of IL-10 and IL-4.
    Qin D; Zeng Y; Qian C; Huang Z; Lv Z; Cheng L; Yao S; Tang Q; Chen X; Lu C
    Cell Microbiol; 2008 Mar; 10(3):713-28. PubMed ID: 18042256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication-competent herpes simplex viral vectors for cancer therapy.
    Markovitz NS; Roizman B
    Adv Virus Res; 2000; 55():409-24. PubMed ID: 11050949
    [No Abstract]   [Full Text] [Related]  

  • 8. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
    Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditionally replicating herpes vectors for cancer therapy.
    Martuza RL
    J Clin Invest; 2000 Apr; 105(7):841-6. PubMed ID: 10749560
    [No Abstract]   [Full Text] [Related]  

  • 10. [Gene therapy for brain tumors: strategy utilizing herpes simplex virus type 1].
    Inoue R; Fujiki M; Kobayashi H
    No Shinkei Geka; 2008 Mar; 36(3):265-76. PubMed ID: 18341016
    [No Abstract]   [Full Text] [Related]  

  • 11. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
    Griffith C; Noonan S; Lou E; Shillitoe EJ
    Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission.
    Mertz GJ
    J Infect Dis; 2008 Oct; 198(8):1098-100. PubMed ID: 18783317
    [No Abstract]   [Full Text] [Related]  

  • 13. Adventitious mutations in clinical grade vectors: an issue to consider?
    Williams DA; Cripe TP
    Mol Ther; 2006 May; 13(5):831-2. PubMed ID: 16595191
    [No Abstract]   [Full Text] [Related]  

  • 14. Fire in the hole: pore dilation of the capsaicin receptor TRPV1.
    Bautista D; Julius D
    Nat Neurosci; 2008 May; 11(5):528-9. PubMed ID: 18437189
    [No Abstract]   [Full Text] [Related]  

  • 15. Functional roles of the tegument proteins of herpes simplex virus type 1.
    Kelly BJ; Fraefel C; Cunningham AL; Diefenbach RJ
    Virus Res; 2009 Nov; 145(2):173-86. PubMed ID: 19615419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
    Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S
    Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.
    Katsura T; Iwai S; Ota Y; Shimizu H; Ikuta K; Yura Y
    Cancer Gene Ther; 2009 Mar; 16(3):237-45. PubMed ID: 18949013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of an aqueous Pelargonium sidoides extract against herpesvirus.
    Schnitzler P; Schneider S; Stintzing FC; Carle R; Reichling J
    Phytomedicine; 2008 Dec; 15(12):1108-16. PubMed ID: 18691858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemia.
    Miki Y; Nonoguchi N; Ikeda N; Coffin RS; Kuroiwa T; Miyatake S
    Neurosurgery; 2007 Sep; 61(3):586-94; discussion 594-5. PubMed ID: 17881973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HSV activity of digitoxin and its possible mechanisms.
    Su CT; Hsu JT; Hsieh HP; Lin PH; Chen TC; Kao CL; Lee CN; Chang SY
    Antiviral Res; 2008 Jul; 79(1):62-70. PubMed ID: 18353452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.